Zhenlong Zhao, Boqiang Fan, Junfeng He, Ying Zhou, Songsong Wu, Shurong Wang, Gang Dong, Jianqin Guo, Ying Wei, Jie Wu, Shiliang Cao, Yan Li, Ming'an Yu
{"title":"热消融与手术切除治疗滤泡性甲状腺肿瘤:一项多中心研究。","authors":"Zhenlong Zhao, Boqiang Fan, Junfeng He, Ying Zhou, Songsong Wu, Shurong Wang, Gang Dong, Jianqin Guo, Ying Wei, Jie Wu, Shiliang Cao, Yan Li, Ming'an Yu","doi":"10.1080/02656736.2025.2539177","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To compare thermal ablation (TA) and surgical resection (SR) for follicular thyroid neoplasm (FTN) with F-TIRADS score lower than 12 points in terms of overall, 1-, 3-, and 5-year progression-free survival rates and complication rates.</p><p><strong>Materials and methods: </strong>In this retrospective study, 692 patients with FTN treated by TA or SR across 9 centers between January 2014 and June 2023 were included. The primary outcomes were overall and 1-, 3-, and 5-year progression-free survival rates and complication rates.</p><p><strong>Results: </strong>As a result, 258 patients (median age: 43.5 years, 205 females) in the TA group and 135 patients (median age: 49 years, 101 females) in the SR group were followed for a median of 23 months and 25 months, respectively. TA resulted in shorter incision length, procedure durations and hospitalization (all <i>p</i> < 0.001). There was no evidence of differences in overall, 1-, 3-, or 5-year progression-free survival rates (all <i>p</i> > 0.05) between TA and SR (5-year: 98.6% vs. 99.4%, <i>p</i> = 0.31). Permanent hoarseness (8.1% [15/135], <i>p</i> < 0.001), permanent hypoparathyroidism (0.7% [1/135], <i>p</i> = 0.74), transient hypoparathyroidism (3.0% [4/135], <i>p</i> = 0.02) and the need for lifelong hormone replacement therapy (64.4% [87/135], <i>p</i> < 0.001) were encountered only in the SR group.</p><p><strong>Conclusion: </strong>There was no evidence of difference in progression-free survival rates between TA and SR for FTN with F-TIRADS score lower than 12 points, and TA resulted in fewer complications and no need of hormone replacement therapy. Therefore, TA is a feasible alternative for selected patients with FTN.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2539177"},"PeriodicalIF":3.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Thermal ablation versus surgical resection for follicular thyroid neoplasm: a multicenter study.\",\"authors\":\"Zhenlong Zhao, Boqiang Fan, Junfeng He, Ying Zhou, Songsong Wu, Shurong Wang, Gang Dong, Jianqin Guo, Ying Wei, Jie Wu, Shiliang Cao, Yan Li, Ming'an Yu\",\"doi\":\"10.1080/02656736.2025.2539177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To compare thermal ablation (TA) and surgical resection (SR) for follicular thyroid neoplasm (FTN) with F-TIRADS score lower than 12 points in terms of overall, 1-, 3-, and 5-year progression-free survival rates and complication rates.</p><p><strong>Materials and methods: </strong>In this retrospective study, 692 patients with FTN treated by TA or SR across 9 centers between January 2014 and June 2023 were included. The primary outcomes were overall and 1-, 3-, and 5-year progression-free survival rates and complication rates.</p><p><strong>Results: </strong>As a result, 258 patients (median age: 43.5 years, 205 females) in the TA group and 135 patients (median age: 49 years, 101 females) in the SR group were followed for a median of 23 months and 25 months, respectively. TA resulted in shorter incision length, procedure durations and hospitalization (all <i>p</i> < 0.001). There was no evidence of differences in overall, 1-, 3-, or 5-year progression-free survival rates (all <i>p</i> > 0.05) between TA and SR (5-year: 98.6% vs. 99.4%, <i>p</i> = 0.31). Permanent hoarseness (8.1% [15/135], <i>p</i> < 0.001), permanent hypoparathyroidism (0.7% [1/135], <i>p</i> = 0.74), transient hypoparathyroidism (3.0% [4/135], <i>p</i> = 0.02) and the need for lifelong hormone replacement therapy (64.4% [87/135], <i>p</i> < 0.001) were encountered only in the SR group.</p><p><strong>Conclusion: </strong>There was no evidence of difference in progression-free survival rates between TA and SR for FTN with F-TIRADS score lower than 12 points, and TA resulted in fewer complications and no need of hormone replacement therapy. Therefore, TA is a feasible alternative for selected patients with FTN.</p>\",\"PeriodicalId\":520653,\"journal\":{\"name\":\"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group\",\"volume\":\"42 1\",\"pages\":\"2539177\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/02656736.2025.2539177\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/02656736.2025.2539177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:比较热消融(TA)和手术切除(SR)治疗F-TIRADS评分低于12分的滤泡性甲状腺肿瘤(FTN)的总体、1年、3年和5年无进展生存率和并发症发生率。材料和方法:本回顾性研究纳入2014年1月至2023年6月9个中心接受TA或SR治疗的692例FTN患者。主要结局是总体、1年、3年和5年无进展生存率和并发症发生率。结果:TA组258例患者(中位年龄:43.5岁,女性205例)和SR组135例患者(中位年龄:49岁,女性101例)的随访时间分别为中位23个月和25个月。TA与SR之间的切口长度、手术时间和住院时间均缩短(p < 0.05)(5年:98.6% vs. 99.4%, p = 0.31)。永久性声音沙哑(8.1% [15/135],p p = 0.74),一过性甲状旁腺功能减退(3.0% [4/135],p = 0.02),需要终身激素替代治疗(64.4% [87/135]),p结论:对于F-TIRADS评分低于12分的FTN, TA与SR的无进展生存率无明显差异,TA并发症少,无需激素替代治疗。因此,对于某些FTN患者,TA是一种可行的替代方案。
Thermal ablation versus surgical resection for follicular thyroid neoplasm: a multicenter study.
Objectives: To compare thermal ablation (TA) and surgical resection (SR) for follicular thyroid neoplasm (FTN) with F-TIRADS score lower than 12 points in terms of overall, 1-, 3-, and 5-year progression-free survival rates and complication rates.
Materials and methods: In this retrospective study, 692 patients with FTN treated by TA or SR across 9 centers between January 2014 and June 2023 were included. The primary outcomes were overall and 1-, 3-, and 5-year progression-free survival rates and complication rates.
Results: As a result, 258 patients (median age: 43.5 years, 205 females) in the TA group and 135 patients (median age: 49 years, 101 females) in the SR group were followed for a median of 23 months and 25 months, respectively. TA resulted in shorter incision length, procedure durations and hospitalization (all p < 0.001). There was no evidence of differences in overall, 1-, 3-, or 5-year progression-free survival rates (all p > 0.05) between TA and SR (5-year: 98.6% vs. 99.4%, p = 0.31). Permanent hoarseness (8.1% [15/135], p < 0.001), permanent hypoparathyroidism (0.7% [1/135], p = 0.74), transient hypoparathyroidism (3.0% [4/135], p = 0.02) and the need for lifelong hormone replacement therapy (64.4% [87/135], p < 0.001) were encountered only in the SR group.
Conclusion: There was no evidence of difference in progression-free survival rates between TA and SR for FTN with F-TIRADS score lower than 12 points, and TA resulted in fewer complications and no need of hormone replacement therapy. Therefore, TA is a feasible alternative for selected patients with FTN.